Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer-Reference-Cited by-同舟云学术

Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer

Published:2017-03 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Aust Stefanie,Felix Sophie,Auer Katharina,Bachmayr-Heyda Anna,Kenner Lukas,Dekan Sabine,Meier Samuel M.,Gerner Christopher,Grimm Christoph,Pils Dietmar

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep42929.pdf

Reference33 articles.

1. Auer, K., Bachmayr-Heyda, A., Aust, S., Grunt, T. W. & Pils, D. Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer. Cancer Lett, doi: 10.1016/j.canlet.2016.11.034 (2016).

2. Auer, K. et al. Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome. Oncotarget 6, 17261–17275, doi: 10.18632/oncotarget.3746 (2015).

3. Auer, K. et al. Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer. Oncotarget 7, 61336–61354, doi: 10.18632/oncotarget.11038 (2016).

4. Bachmayr-Heyda, A. et al. Small RNAs and the competing endogenous RNA network in high grade serous ovarian cancer tumor spread. Oncotarget 7, 39640–39653, doi: 10.18632/oncotarget.9243 (2016).

5. Karnezis, A. N., Cho, K. R., Gilks, C. B., Pearce, C. L. & Huntsman, D. G. The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nat Rev Cancer 17, 65–74, doi: 10.1038/nrc.2016.113 (2017).

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Potential of Natural Killer Cell-Based Immunotherapy in Targeting High-Grade Serous Ovarian Carcinomas;Vaccines;2024-06-18

2. Targeting tumour markers in ovarian cancer treatment;Clinica Chimica Acta;2024-06

3. AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication;British Journal of Cancer;2024-02-09

4. NLRC5 overexpression in ovarian tumors remodels the tumor microenvironment and increases T-cell reactivity toward autologous tumor-associated antigens;Frontiers in Immunology;2024-01-03

5. Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success;Cancers;2023-12-02